ENPP2 and metabolic dysfunction-associated steatotic liver disease: reported an AUC of 0.75 for the efficacy of serum ATX in diagnosing liver fibrosis stages ≥ 3 for all patients with NAFLD (AUC 0.74 for male patients and 0.78 for female patients) [51].